Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes

Diabetes Care. 2021 Mar;44(3):e45-e47. doi: 10.2337/dc20-2265. Epub 2021 Jan 12.

Patrick R Lawler^{1

2

3}, Hongyan Liu^{4

5}, Claudia Frankfurter⁶, Leif Erik Lovblom⁷, Yuliya Lytvyn^{8

6}, Dylan Burger⁹, Kevin D Burns⁹, Davor Brinc^{10

11}, David Z I Cherney^{8

5

12}

¹ Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
² Ted Rogers Centre for Heart Research, University of Toronto, Toronto, Ontario, Canada.
³ Heart & Stroke/Richard Lewar Centres of Excellence in Cardiovascular Research, University of Toronto, Toronto, Ontario, Canada.
⁴ Division of Nephrology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada [email protected].
⁵ Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
⁶ Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁷ Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
⁸ Division of Nephrology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
⁹ Division of Nephrology, Department of Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
¹⁰ Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.
¹¹ Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
¹² Department of Physiology and Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.

No abstract available

Publication types